Predictive factors for hepatocellular carcinoma recurrence after curative treatments

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm worldwide. Recurrence of HCC after resection or loco-regional therapies represents an important clinical issue as it affects up to 70% of patients. This can be divided into early or late, if it occurs within or after 24 months after treatment, respectively. While the predictive factors for early recurrence are mainly related to tumour biology (local invasion and intrahepatic metastases), late recurrences are mainly related to de novo tumour formation. Thus, it is important to recognize these factors prior to any treatment in each patient, in order to optimize the treatment strategy and follow-up after treatment. The aim of this review is to summarize the current evidence available regarding predictive factors for the recurrence of HCC, according to the different therapeutic strategies available. In particular, we will discuss the role of new ultrasound-based techniques and biological features, such as tumor-related and circulating biomarkers, in predicting HCC recurrence. Recent advances in imaging-related parameters in computed-tomography scans and magnetic resonance imaging will also be discussed.

Keywords

Liver resection / trans-arterial chemoembolization / radiofrequency ablation / liver stiffness measurement / indocyanine green retention test

References

[1] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[2] European Association for the Study of the LiverEASL Clinical Practice Guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[3] Kanwal F,Asch SM,Li L.Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents..Hepatology2020;71:44-55

[4] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[5] Dufour JF,Raymond E,De T.Clinical practice guidelines EASL - EORTC clinical practice guidelines: management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer..J Hepatol2012;56:908-43

[6] Omata M,Kokudo N,Lee JM.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update..Hepatol Int2017;11:317-70 PMCID:PMC5491694

[7] Bruix J,Sherman M.Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma..Gastroenterology2016;150:835-53

[8] Colecchia A,Cucchetti A,Taddia M.Prognostic factors for hepatocellular carcinoma recurrence..World J Gastroenterol2014;20:5935-50 PMCID:PMC4033434

[9] D’Amico G,Pagliaro L.Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies..J Hepatol2006;44:217-31

[10] Zhou JY,Li L,Zhou YH.High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study..Virol J2012;9:16 PMCID:PMC3349554

[11] Poon RT,Ng IO,Liu CL.Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma..Cancer2000;89:500-7

[12] Tung-Ping Poon R,Wong J.Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma..Ann Surg2000;232:10-24 PMCID:PMC1421103

[13] Imamura H,Tanaka E,Hasegawa K.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy..J Hepatol2003;38:200-7

[14] Llovet JM,Mazzaferro V.Resection and liver transplantation for hepatocellular carcinoma..Semin Liver Dis2005;25:181-200

[15] Qu LS,Zhu J.Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load..Ann Hepatol2017;16:412-20

[16] Jung KS,Kim SU,Kim BK.Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: Development and validation of a predictive model..PLoS One2014;9:e99167 PMCID:PMC4049628

[17] Marasco G,Colli A,Casazza G.Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection..J Hepatol2019;70:440-8

[18] Yamamoto Y,Morimura R,Murayama Y.Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy..World J Gastroenterol2015;21:1207-15 PMCID:PMC4306165

[19] Roayaie S,Thung SN,Fiel MI.A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma..Gastroenterology2009;137:850-5 PMCID:PMC2739450

[20] Pawlik TM,Vauthey JN.Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations..Liver Transpl2004;10:S74-80

[21] Ripoll C,Garcia-Tsao G,Burroughs A.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis..Gastroenterology2007;133:481-8

[22] Colecchia A,Casazza G,Schiumerini R.Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study..J Hepatol2014;60:1158-64

[23] Colecchia A,Taddia M,Eusebi LH.Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature..Eur J Gastroenterol Hepatol2015;27:992-1001

[24] Colecchia A,Marasco G.Berzigotti A.Spleen stiffness by ultrasound elastography..Diagnostic methods for cirrhosis and portal hypertension.2018;Cham, Springer International Publishing113-37

[25] Ripoll C,Garcia-Tsao G,Grace N.Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis..J Hepatol2009;50:923-8 PMCID:PMC3721146

[26] Jung KS,Choi GH,Park YN.Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan®)..Ann Surg Oncol2012;19:4278-86

[27] Kamiyama T,Yokoo H,Tahara M.Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma..World J Surg Oncol2012;10:107 PMCID:PMC3407774

[28] Liu L,Yang H,Zhao Y.Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China..Am J Surg2012;203:741-50

[29] Pawlik TM,Vauthey JN,Ng IOL.Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma..Liver Transplant2005;11:1086-92

[30] Colecchia A,Montrone L,Di Biase AR.Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment..J Hepatol2011;54:300-5

[31] Pawlik TM,Anders RA,Maley W.Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy..Ann Surg2007;245:435-42 PMCID:PMC1877015

[32] Jung SM,Choi GS,Yi NJ.Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma..J Gastrointest Surg2019;23:304-11

[33] Lau WY,Chen PJ,Chow P.Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90..Oncology2013;84:311-8

[34] Mazzaferro V,Bhoori S,Chiesa C.Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study..Hepatology2013;57:1826-37

[35] Hirokawa F,Miyamoto Y,Shimizu T.Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma..Hepatol Res2014;44:846-53

[36] Kaibori M,Matsui K.Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma..J Surg Oncol2010;102:462-8

[37] Rodríguez-Perálvarez M,Andreana L,Dhillon AP.A systematic review of microvascular invasion in hepatocellular carcinoma: Diagnostic and prognostic variability..Ann Surg Oncol2013;20:325-39

[38] Kim JM,Yi NJ,Kim K.Predicting hepatocellular carcinoma recurrence beyond milan criteria after liver resection for solitary hepatocellular carcinoma..J Gastrointest Surg2019;Epub ahead of print. doi: 10.1007/s11605-019-04363-1

[39] Zhao H,Lu Z,Zhu L.Prognostic value and preoperative predictors of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm without macrovascular invasion..Oncotarget2017;8:61203-14 PMCID:PMC5617417

[40] Cucchetti A,Ercolani G,Torzilli G.A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma..Ann Surg Oncol2012;19:3697-705

[41] Shi M,Lin XJ,Chen MS.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma..Ann Surg2007;245:36-43 PMCID:PMC1867934

[42] Lai ECS,Ng IOL.The pathological basis of resection margin for hepatocellular carcinoma..World J Surg1993;17:786-90

[43] Tsilimigras DI,Moris D,Paredes AZ.Effect of surgical margin width on patterns of recurrence among patients undergoing R0 hepatectomy for T1 hepatocellular carcinoma: an international multi-institutional analysis..J Gastrointest Surg2019;Epub ahead of print. doi: 10.1007/s11605-019-04275-0

[44] Belghiti J,Farges O,Fekete F.Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis..Ann Surg1991;214:114-7 PMCID:PMC1358509

[45] Guo Y,Koh YX,Cheow PC.Preoperative predictors including the role of inflammatory indices in predicting early recurrence after re-resection for recurrent hepatocellular carcinoma..World J Surg2019;43:2587-94

[46] Tabrizian P,Shrager B,Roayaie S.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis..Ann Surg2015;261:947-55

[47] Zhang X,Xu L,Feng S.Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection..Hepatol Int2019;13:715-25

[48] Liao M,Liao Y,Yao W.Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection..Onco Targets Ther2018;11:5591-600 PMCID:PMC6135434

[49] Hung HC,Cheng CH,Wang YC.Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection..J Hepatobiliary Pancreat Sci2017;24:559-69

[50] Zheng J,Li H,He L.Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review..Cell Physiol Biochem2017;44:967-81

[51] Itoh S,Shimokawa M,Mano Y.Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection..BJS Open2019;3:500-8 PMCID:PMC6677099

[52] Liao M,Liao Y,Yu J.Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with single tumor size ≤ 5 cm hepatocellular carcinoma after radical resection..Front Oncol2019;9:347 PMCID:PMC6536585

[53] Shi S,Ye L,Li X.Prognostic value of systemic inflammation score in patients with hepatocellular carcinoma after hepatectomy..Oncotarget2017;8:79366-75 PMCID:PMC5668048

[54] Wu J,Tian L,Wang BL.Serum IgG4: IgG ratio predicts recurrence of patients with hepatocellular carcinoma after curative resection..J Cancer2017;8:1338-46 PMCID:PMC5479238

[55] Chan AWH,Berhane S,Cucchetti A.Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection..J Hepatol2018;69:1284-93

[56] Tokumitsu Y,Tokuhisa Y,Matsukuma S.A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy..Oncol Lett2018;15:4411-22 PMCID:PMC5844062

[57] Cabibbo G,Calvaruso V,Cannavò MR.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study..Aliment Pharmacol Ther2017;46:688-95

[58] Petta S,Barbara M,Bucci L.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon..Aliment Pharmacol Ther2017;45:160-8

[59] Singal AG,Mehta N,Pillai A.Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study..Gastroenterology2019;156:1683-92.e1 PMCID:PMC6598433

[60] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[61] Wu JC,Chau GY,Lai CR.Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma..J Hepatol2009;51:890-7

[62] Donato F,Gelatti U,Boffetta P.Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women..Am J Epidemiol2002;155:323-31

[63] Kudo A,Ban D,Irie T.Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis..J Gastroenterol2014;49:1352-61

[64] Bai F,Ma M,Lyu J.A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma..Mol Oncol2018;12:1125-37 PMCID:PMC6026871

[65] Vasuri F,De Pace V,Bertuzzo V.Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas..Oncotarget2018;9:17895-905 PMCID:PMC5915163

[66] Oh J,Park J,Yoon JH.Hepatocellular carcinoma: Texture analysis of preoperative computed tomography images can provide markers of tumor grade and disease-free survival..Korean J Radiol2019;20:569-79 PMCID:PMC6424831

[67] Lee S,Hwang JA,Ha SY.Pre-operative ADC predicts early recurrence of HCC after curative resection..Eur Radiol2019;29:1003-12

[68] Rimola J,Sapena V,Darnell A.Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma..Eur Radiol2020;30:186-94

[69] Ahn SJ,Park SJ,Han JK.Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis..Abdom Radiol2019;44:539-48

[70] Lee S,Lee JE,Park CK.Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma..J Hepatol2017;67:526-34

[71] Shan Q,Feng S,Chen S.CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation..Cancer Imaging2019;19:11 PMCID:PMC6391838

[72] Lambin P,Leijenaar R,Van Stiphout RGPM.Radiomics: extracting more information from medical images using advanced feature analysis..Eur J Cancer2012;48:441-6 PMCID:PMC4533986

[73] Kim S,Kim DY,Kim MJ.Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma..Clin Cancer Res2019;25:3847-55

[74] Zheng J,Chapman WC,Gonen M.Preoperative prediction of microvascular invasion in hepatocellular carcinoma using quantitative image analysis..J Am Coll Surg2017;225:778-88.e1 PMCID:PMC5705269

[75] Wang J,Liu Y,Kuang S.3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting tumor recurrence..J Magn Reson Imaging2019;49:719-30 PMCID:PMC6731763

[76] Fujiwara N,Kudo Y,Taguri M.Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma..J Hepatol2015;63:131-40

[77] Lee JI,Kim SU,Lee KS.Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis..Cancers (Basel)2019;11:425 PMCID:PMC6468874

[78] Zhang J,Li C,Xiang H.The combination of the preoperative albumin-bilirubin grade and the fibrosis-4 index predicts the prognosis of patients with hepatocellular carcinoma after liver resection..Biosci Trends2019;13:351-7

[79] Johnson PJ,Kagebayashi C,Teng M.A nssessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach - the albi grade..J Clin Oncol2015;33:550-8 PMCID:PMC4322258

[80] Lee YH,Hur YH,Kim HJ.Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma..Ann Hepato-Biliary-Pancreatic Surg2018;22:335 PMCID:PMC6295378

[81] Amisaki M,Morimoto M,Sakamoto T.Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection..Hepatobiliary Pancreat Dis Int2018;17:502-9

[82] Matsushima H,Ryu T,Tateishi M.Prognosis of hepatocellular carcinoma patients who achieved long-term recurrence-free survival after curative therapy: impact of the ALBI grade..J Gastrointest Surg2018;22:1230-8

[83] Johnson PJ,Kagebayashi C,Teng M.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade..J Clin Oncol2015;33:550-8 PMCID:PMC4322258

[84] Lin CY,Wang CC,Hu TH.The ALBI grade is a good predictive model for very late recurrence in patients with hepatocellular carcinoma undergoing primary resection..World J Surg2020;44:247-57

[85] Lin CW,Lin CC,Lo GH.Clinical and translational gastroenterology autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection..Clin Transl Gastroenterol2018;9:166 PMCID:PMC6026596

[86] Song Q,Hu W,Yang X.Downregulation of epstein-barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection..Oncol Lett2018;15:7751-9 PMCID:PMC5934722

[87] Fang Y,Janssen HLA,Dong L.Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence..J Dig Dis2018;19:155-69

[88] Hoki T,Yan L,Ito F.Low DMT1 expression associates with increased oxidative phosphorylation and early recurrence in hepatocellular carcinoma..J Surg Res2019;234:343-52 PMCID:PMC6291835

[89] Chang YY,Chan SH,Lee YP.NEK2 promotes hepatoma metastasis and serves as biomarker for high recurrence risk after hepatic resection..Ann Hepatol2018;17:843-56

[90] Ji F,Zhang Y,Cao QH.Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection..BMC Cancer2018;18:460 PMCID:PMC5926532

[91] Huang CF,Chang WT,Huang CI.Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection..Sci Rep2018;8:15821 PMCID:PMC6202341

[92] Lv Y,Huang Z,Fang Y.Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection..Hepatol Res2018;48:1140-8

[93] Wang Y,Handoko YA,Shi M.NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection..Int J Cancer2019;145:662-70

[94] Gao XH,Chen H,Xie W.Lipoprotein (A): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection..Onco Targets Ther2018;11:5917-24 PMCID:PMC6149830

[95] Xu Q,Gu S,Zhang J.A novel inflammation-based prognostic score: The fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma..J Immunol Res2018;2018:4925498 PMCID:PMC6031154

[96] Oh TK,Cho JY,Han HS.The high-sensitivity C-reactive protein/albumin ratio predicts long-term oncologic outcomes after curative resection for hepatocellular carcinoma..J Clin Med2018;7:139 PMCID:PMC6024983

[97] Li C,Peng W,Yan LN.Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection..Medicine (Baltimore)2018;97:e11599 PMCID:PMC6086466

[98] Abbate V,Giuliante F,Gatto I.HepPar1-positive circulating microparticles are increased in subjects with hepatocellular carcinoma and predict early recurrence after liver resection..Int J Mol Sci2017;18:1043 PMCID:PMC5454955

[99] Aryal B,Shimizu T,Furoi A.Predictive value of diminished serum PDGF-BB after curative resection of hepatocellular cancer..J Oncol2019;2019:1925315 PMCID:PMC6339767

[100] Liu H,Wu X,Wang Y.The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection..Cancer Manag Res2019;11:2935-46 PMCID:PMC6497822

[101] Toyoda H,Tada T,Maeda A.Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection..Liver Int2016;36:293-301

[102] Kim HS,Kim BK,Kim DY.Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection..Clin Mol Hepatol2020;26:33-44 PMCID:PMC6940487

[103] Lee JH,Kim DY,Han KH.Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib..Liver Int2011;31:1144-9

[104] Cescon M,Cucchetti A,Montrone L.Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma..Ann Surg2012;256:706-13

[105] Eguchi S,Arii S,Okita K.Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey..Surgery2008;143:469-75

[106] Xu XF,Han J,Lau WY.Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China..In: JAMA Surg2019;154:209-17 PMCID:PMC6439634

[107] Chan EEH.A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores..Jpn J Clin Oncol2016;47:287-93

[108] Testino G,Borro P.Alcohol and hepatocellular carcinoma: a review and a point of view..World J Gastroenterol2014;20:15943-54 PMCID:PMC4239482

[109] Shinkawa H,Takemura S,Aota T.Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C..Ann Gastroenterol Surg2018;2:319-26 PMCID:PMC6036378

[110] Qin W,Hu B,Tian H.A novel score predicts HBV-related hepatocellular carcinoma recurrence after hepatectomy: a retrospective multicenter study..J Gastrointest Surg2019;23:922-32

[111] Colecchia A,Scaioli E,Colli A.Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis..Gastroenterology2012;143:646-54

[112] Festi D,Ravaioli F,Colecchia A.Role and clinical meaning of non-invasive tests in the evaluation of portal hypertension in patients with advanced chronic liver disease..Recenti Prog Med2018;109:574-84

[113] Marasco G,Dajti E,Cucchetti A.Prediction of posthepatectomy liver failure: role of SSM and LSPS..J Surg Oncol2019;119:400-1

[114] Korean Liver Cancer Association (KLCA); National Cancer Center (NCC)2018 Korean liver cancer association-national cancer center korea practice guidelines for the management of hepatocellular carcinoma..Korean J Radiol2019;20:1042-113 PMCID:PMC6609431

[115] Livraghi T,Monti F,Vettori C.US-guided percutaneous alcohol injection of small hepatic and abdominal tumors..Radiology1986;161:309-12

[116] Shiina S,Imamura M,Koike Y.Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors..Liver Int2012;32:1434-42 PMCID:PMC3466412

[117] Bruix J.Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[118] Khan KN,Yamasaki K,Inoue O.Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection..J Hepatol2000;32:269-78

[119] Germani G,Gurusamy K,Isgrò G.Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis..J Hepatol2010;52:380-8

[120] Ebara M,Kita K,Fukuda H.Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation..J Hepatol2005;43:458-64

[121] Koda M,Mitsuda A,Horie Y.Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma..Cancer2000;88:529-37

[122] Ohnishi K,Ito S.Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma..Hepatology1998;27:67-72

[123] Shiina S,Unuma T,Yoshiura K.Percutaneous ethanol injection therapy for hepatocellular carcinoma. a histopathologic study..Cancer1991;68:1524-30

[124] Lin SM,Lin CC,Chen YC.Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm..Gastroenterology2004;127:1714-23

[125] Lin SM,Lin CC,Chen YC.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less..Gut2005;54:1151-6 PMCID:PMC1774888

[126] Hines-Peralta A,Horkan C,Goldberg SN.Chemical tumor ablation with use of a novel multiple-tine infusion system in a canine sarcoma model..J Vasc Interv Radiol2006;17:351-8

[127] Livraghi T,Di Stasi M,Solbiati L.Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?.Hepatology2008;47:82-9

[128] Lencioni R.Local-regional treatment of hepatocellular carcinoma..Radiology2012;262:43-58

[129] Lurje I,Bednarsch J,Isfort P.Treatment strategies for hepatocellular carcinoma - a multidisciplinary approach..Int J Mol Sci2019;20:1465 PMCID:PMC6470895

[130] Ganne-Carrié N,Ziol M,Nahon P.Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma..Hepatic Oncol2014;1:395-408 PMCID:PMC6095149

[131] Zytoon AA,Murakami K,Furuse J.Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome..Jpn J Clin Oncol2007;37:658-72

[132] Bruix J,Llovet JM.Chemoembolization for hepatocellular carcinoma..Gastroenterology2004;127:S179-88

[133] Sandow TA,Albar AA,Kirsch DS.Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort..Radiology2018;286:1072-83

[134] Yamakado K,Nakatsuka A,Fujimori M.Radiofrequency ablation for hepatocellular carcinoma..Gastrointest Interv2014;3:35-9

[135] Poon RTP,Yu WC,Wong J.High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study..Oncol Rep2004;11:1077-84

[136] Liao X,Li X,Deng W.Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization..J Huazhong Univ Sci Technolog Med Sci2003;23:280-2

[137] Sergio A,Cardin R,Ragazzi R.TTranscatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness..Am J Gastroenterol2008;103:914-21

[138] Xuan ZD,Wang Y.Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization..Expert Rev Anticancer Ther2017;17:1169-78

[139] Katyal S,Peterson MS,Baron RL.Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis..Am J Roentgenol2000;175:1665-72

[140] Lee YK,Kim DY,Lee KH.Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization..BMC Cancer2013;13:5 PMCID:PMC3545962

[141] Kim BK,Seong JS,Kim DY.Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma..Liver Int2011;31:369-76

[142] Riaz A,Kulik LM,Lewandowski RJ.Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival..J Clin Oncol2009;27:5734-42

[143] Yang Z,Lu Y,Tang B.Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizations..Oncotarget2015;6:43090-8 PMCID:PMC4767493

[144] Shen Y,Li W.Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA..J Clin Lab Anal2019;33:e22999 PMCID:PMC6868405

[145] Cai XR,Liu MM,Zhang XP.Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy..J Cancer2018;9:2380-8 PMCID:PMC6036717

[146] Kim JH,Lee JH,Cho SK.Novel albumin–bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization..Dig Dis Sci2018;63:1062-71

[147] Chung GE,Lee JH,Yoon JH.Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy..J Gastroenterol Hepatol2011;26:1638-45

[148] Sohn W,Lee MW,Lim HK.Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation..Scand J Gastroenterol2014;49:373-80

[149] Kim SS,Cho HJ,Kim JW.Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma..J Gastroenterol Hepatol2017;32:199-207

[150] Cui L,Bai B.Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma..Cell Physiol Biochem2015;37:276-83

[151] Lu YL,Huang XY,Wu XM.Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma..Sci Rep2016;6:36104 PMCID:PMC5086876

[152] Ali HEA,Zeeneldin AA,Tabashy R.Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization..Clin Biochem2019;65:45-52 PMCID:PMC6397777

[153] Gao Y,Cui Z,Liu YZ.Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation..World J Gastroenterol2015;21:10418-26 PMCID:PMC4579888

[154] Kim SH,Lim HK.Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography..J Comput Assist Tomogr2007;31:198-203

[155] Kokabi N,Camacho JC,Mittal PK.Baseline and early MR apparent diffusion coefficient quantification as a predictor of response of unresectable hepatocellular carcinoma to doxorubicin drug-eluting bead chemoembolization..J Vasc Interv Radiol2015;26:1777-86

[156] Kim HC,Han JK,Lee JY.Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images..Radiology2002;225:773-80

[157] Ebied OM,Carr BI,Li W.Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma..Cancer2003;97:1042-50

[158] Park HJ,Choi SY,Park SJ.Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings..Am J Roentgenol2017;209:W211-20

[159] Maesaka K,Yamada R,Urabe A.Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma..Hepatol Res2020;50:365-73

[160] Choi SJ,Seo J,Lee JM.Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization..Abdom Imaging2014;39:518-25

[161] Huppertz A,Kraus A,Scheidler J.Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations..Radiology2005;234:468-78

[162] Ishimaru H,Sakugawa T,Matsuoka Y.Local recurrence after chemoembolization of hepatocellular carcinoma: uptake of gadoxetic acid as a new prognostic factor..Am J Roentgenol2014;202:744-51

[163] Ou HY,Chuang YH,Chen CL.Quantification of functional MR predicts early response in post-doxorubicin drug-eluting beads chemoembolization for hepatocellular carcinoma..Dig Dis Sci2019;Epub ahead of print. doi: 10.1007/s10620-019-05951-6

[164] Kobayashi T,Nakano O,Kamimura H.Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies..BMC Cancer2018;18:756 PMCID:PMC6056944

[165] Eggert T.Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma..Digestion2017;96:1-4 PMCID:PMC5548590

[166] Minami Y.Radiofrequency ablation of hepatocellular carcinoma: current status..World J Radiol2010;2:417 PMCID:PMC3006479

[167] Lau WY.The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review..Ann Surg2009;249:20-5

[168] Na BG,Oh DK,Kang TW.Clinical outcomes of laparoscopic radiofrequency ablation of single primary or recurrent hepatocellular carcinoma (≤ 3 cm)..Ann Surg Treat Res2017;92:355-60 PMCID:PMC5416922

[169] Lencioni R,Crocetti L,Della Pina C.Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation..Radiology2005;234:961-7

[170] Nault JC,Nahon P,Séror O.Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations..J Hepatol2018;68:783-97

[171] Toshimori J,Nakamura S,Morimoto Y.Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location..Acta Med Okayama2015;69:205-12

[172] Tiong L.Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma..Br J Surg2011;98:1210-24

[173] Sparchez Z,Radu P,Sparchez M.Prognostic factors after percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma. Impact of incomplete ablation on recurrence and overall survival rates..J Gastrointest Liver Dis2018;27:399-407

[174] Wu CY,Ho HJ,Kuo KN.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection..JAMA2012;308:1906-13

[175] N’Kontchou G,Aout M,Grando V.Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis..Hepatology2009;50:1475-83

[176] European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del HigadoEASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis..J Hepatol2015;63:237-64

[177] Rekik S,Mumana A,Nkontchou G.Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis..J Gastroenterol Hepatol2020;35:142-50

[178] Llovet JM,Montaña X,Coll S.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[179] Kong J,Fan H,Zhao H.Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma..Medicine (Baltimore)2018;97:e11872 PMCID:PMC6112993

[180] Liapi E,Hong K.Transcatheter arterial chemoembolization: current technique and future promise..Tech Vasc Interv Radiol2007;10:2-11

[181] Sieghart W,Peck-Radosavljevic M.Transarterial chemoembolization: modalities, indication, and patient selection..J Hepatol2015;62:1187-95

[182] Dhanasekaran R,Staley CA,Khanna V.Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin Drug Eluting Beads (DEB) for unresectable Hepatocelluar Carcinoma (HCC)..J Surg Oncol2010;101:476-80

[183] Poon RTP,Pang RWC,Woo R.A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead..Clin Gastroenterol Hepatol2007;5:1100-8

[184] Yamaguchi R,Iemura A,Haramaki M.Expression of vascular endothelial growth factor in human hepatocellular carcinoma..Hepatology1998;28:68-77

[185] Ogasawara S,Iemura A,Kojiro M.Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines..Hepatology1996;24:198-205

[186] Zhu CB,Chen LL,Zhang SC.Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma..PLoS One2012;7:e44648 PMCID:PMC3435289

[187] Casadei Gardini A,Foschi FG,Andreone P.Imbalance of neutrophils and lymphocyte counts can be predictive of hepatocellular carcinoma occurrence in hepatitis C-related cirrhosis treated with direct-acting antivirals..Gastroenterology2018;154:2281-2

[188] Casadei Gardini A,Conti F,Vukotic R.Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals..Dig Liver Dis2019;51:681-8

[189] Wang B,Cheng L,Wu B.The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma..Futur Oncol2019;15:827-39

[190] Wu YQ,Xue M,Wei JL.25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization..Clin Transl Oncol2020;22:70-80

[191] Zhang JB,Zhang B,Zhang L.Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization..Eur J Gastroenterol Hepatol2011;23:787-93

[192] Shen H,Chen R,Xu X.Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization..Medicine (Baltimore)2017;96:e7438 PMCID:PMC5515752

[193] Liu PH,Hsia CY,Su CW.Prognosis of hepatocellular carcinoma: assessment of eleven staging systems..J Hepatol2016;64:601-8

[194] Biselli M,Gramenzi A,Cursaro C.Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study..Clin Gastroenterol Hepatol2005;3:918-25

[195] Brown DB,Lisker-Melman M,Pilgram TK.Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma..J Vasc Interv Radiol2004;15:1209-18

[196] Testa R,Giannini E,Malfatti F.Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: Role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatm..Aliment Pharmacol Ther2003;17:1563-9

[197] Xu L,Chen MS,Zhang YJ.Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization..J Hepatol2015;63:122-30

[198] Sasaki R,Miyazoe Y,Nakashiki S.Ketone bodies as a predictor of prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization..Nutrition2018;50:97-103

[199] Yu X,Guo X,Liang J.Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus..PLoS One2014;9:e93416 PMCID:PMC3981717

[200] Hu W,Dong L,Li C.MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy..Anticancer Drugs2019;30:233-40

[201] Zhang H,Dai J,Ge N.Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients..Med Oncol2014;31:1-8

[202] Liang KH,Chen SF,Yang PC.GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization..Pharmacogenomics2016;17:353-66

[203] Wang G.Correlations of pri-Let-7 gene polymorphisms with the recurrence and metastasis of primary liver cancer after transcatheter arterial chemoembolization..Pathol Res Pract2018;214:667-72

[204] Fako V,Pomyen Y,Chaisaingmongkol J.Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization..Int J Biol Sci2019;15:2654-63 PMCID:PMC6854367

[205] Spârchez Z,Radu P,Comsa M.Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma..Med Ultrason2016;18:96-102

[206] Sung SA,Joon SL,Yong EC.Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma..Radiology2010;255:459-66

[207] Hwang J,Kim YS,Woo JY.Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy..J Magn Reson Imaging2010;32:629-38

[208] Tacher V,Duran R,Lee H.Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach..Radiology2016;278:275-84 PMCID:PMC4695977